# Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

> **NCT00460265** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 658 (actual)

## Conditions studied

- Recurrent and/or Metastatic Head and Neck Cancer

## Interventions

- **DRUG:** ARM 2
- **DRUG:** ARM 1

## Key facts

- **NCT ID:** NCT00460265
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-05
- **Final completion:** 2012-05
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2014-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460265, "Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00460265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*